{
  "id": 17178738,
  "title": "Laurus Labs hits 52-week high as strong Q2 results fuel buying",
  "url": "https://urgent.news/2026/10/30/laurus-labs-hits-52-week-high-as-strong-q2-results-fuel-buying",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-30T05:04:03.000Z",
  "source": {
    "name": "Hindu BusinessLine",
    "slug": "hindu-businessline",
    "url": "https://www.thehindubusinessline.com/markets/stock-markets/laurus-labs-hits-52-week-high-as-strong-q2-results-fuel-buying/article71643687.ece"
  },
  "original_language": "en",
  "account": "Laurus Labs experienced a surge in its stock price on Friday, reaching a fresh 52-week high of ₹2,343, following strong Q2 results that impressed investors. The company's shares climbed 3.81 per cent to ₹2,329.60 on the NSE in early trade, marking a significant increase of over 139 per cent in the past year and 109 per cent year-to-date. Motilal Oswal, in a note dated October 30, upgraded its rating to Buy and set a revised target price of ₹2,830, indicating a potential upside of about 26 per cent from the previous close of ₹2,244. The brokerage firm cited several factors contributing to the company's growth, including the scale-up of its Contract Development and Manufacturing Organization (CDMO) segment, particularly in peptide manufacturing, a steady rise in affordable medicine supply, and a more favorable segmental mix. Laurus Labs reported a 33 per cent year-on-year increase in net revenue for Q2 FY27, reaching ₹2,206 crore, up from ₹1,653 crore the previous year. EBITDA improved to ₹750 crore from ₹403 crore a year ago, with net profit nearly tripling to ₹436 crore from ₹194 crore. The company's strong performance was primarily driven by the CDMO small molecules segment, which grew by 86 per cent year-on-year. The company also announced plans to acquire a 60 per cent stake in Canada-based Galenvs Sciences and a 52 per cent stake in Hyderabad-based SI & C Resins to bolster its oligonucleotide capabilities and peptide manufacturing.",
  "summary": "The stock has gained over 139% in the past year and is up 109% year-to-date",
  "key_points": [
    "Laurus Labs reaches ₹2,343 52-week high post strong Q2 results",
    "Shares up 3.81% to ₹2,329.60 on NSE, 139% increase year-over-year",
    "Motilal Oswal upgrades rating to Buy, targets ₹2,830 with 26% upside"
  ],
  "editors_take": "The rapid expansion of the contract manufacturing segment and strategic acquisitions signal a shift toward specialized peptide and oligonucleotide production to drive long-term revenue growth.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}